Biotechnology is a dynamic and complex industry offering enormous potential for commercial and social rewards. Yet biotech companies confront a unique pattern of business and legal needs. Frequently, they face the dual challenge of securing, developing and commercializing unique technology, while at the same time growing and funding a business until anticipated revenues arrive. This requires building a bullet proof foundation of intellectual property, navigating a complex array of regulations, growing value to attract and support investment, and, increasingly, entering into a wide array of strategic alliances at home and abroad.

McCandlish Holton offers biotechnology clients which are grounded in the firm's years of experience in health care, intellectual property and tech transfer, corporate formation and governance, and capital formation.

The firm strives to meet the needs of biotech companies by implementing comprehensive and successful strategy for creating value, as well as to responding to day-to-day business, legal and regulatory challenges and opportunities. We provide a wide range of intellectual property services, including strategic planning, negotiating and drafting university and federal tech transfer and CRADA agreements, contract research and material transfer agreements, all varieties of licenses, and structuring and implementing relationships with inventors, employees, consultants and vendors. The firm structures, negotiates and drafts private placement, venture capital and other capital formation transactions, as well as strategic alliance and other co-development agreements as creative as the circumstances demand.

The firm's clients have included individual inventors, research institutes and consortia, universities, hospitals, U.S. and foreign biotech companies at various stages of development and industry associations.

For further information on the McCandlish Holton Biotechnology Group, please contact Genevieve K. Dybing.